SG Americas Securities LLC acquired a new position in shares of TherapeuticsMD Inc (NASDAQ:TXMD) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 105,217 shares of the company’s stock, valued at approximately $554,000. SG Americas Securities LLC owned 0.05% of TherapeuticsMD at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of TXMD. Managed Account Services Inc. grew its stake in shares of TherapeuticsMD by 5.5% during the second quarter. Managed Account Services Inc. now owns 19,103 shares of the company’s stock worth $101,000 after purchasing an additional 1,000 shares in the last quarter. Traynor Capital Management Inc. grew its stake in shares of TherapeuticsMD by 14.0% during the second quarter. Traynor Capital Management Inc. now owns 22,799 shares of the company’s stock worth $123,000 after purchasing an additional 2,799 shares in the last quarter. Greenwood Capital Associates LLC grew its stake in shares of TherapeuticsMD by 17.5% during the first quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock worth $146,000 after purchasing an additional 3,022 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its stake in shares of TherapeuticsMD by 56.1% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company’s stock worth $207,000 after purchasing an additional 10,330 shares in the last quarter. Finally, Carl Domino Inc acquired a new position in shares of TherapeuticsMD during the second quarter worth $235,000.
TXMD has been the subject of a number of analyst reports. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 target price on shares of TherapeuticsMD in a research note on Wednesday, May 24th. Oppenheimer Holdings, Inc. upgraded shares of TherapeuticsMD from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a research note on Tuesday, July 11th. Cantor Fitzgerald reiterated an “overweight” rating and set a $33.00 target price on shares of TherapeuticsMD in a research note on Friday, July 21st. CIBC upgraded shares of TherapeuticsMD from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 11th. Finally, Jefferies Group LLC set a $15.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a research note on Wednesday, June 14th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. TherapeuticsMD has a consensus rating of “Buy” and an average target price of $14.88.
ILLEGAL ACTIVITY NOTICE: “SG Americas Securities LLC Takes $554,000 Position in TherapeuticsMD Inc (TXMD)” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://sportsperspectives.com/2017/09/11/sg-americas-securities-llc-takes-554000-position-in-therapeuticsmd-inc-txmd.html.
In other news, Director Tommy G. Thompson purchased 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The shares were purchased at an average price of $5.99 per share, with a total value of $29,950.00. Following the purchase, the director now directly owns 3,555 shares of the company’s stock, valued at approximately $21,294.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
TherapeuticsMD Inc (NASDAQ:TXMD) opened at 6.61 on Monday. The company’s 50 day moving average is $5.86 and its 200-day moving average is $5.57. TherapeuticsMD Inc has a 52 week low of $3.50 and a 52 week high of $8.30. The firm’s market cap is $1.35 billion.
TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Thursday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. TherapeuticsMD had a negative net margin of 462.94% and a negative return on equity of 77.41%. The firm had revenue of $4.25 million for the quarter, compared to the consensus estimate of $4.91 million. During the same quarter in the previous year, the firm posted ($0.11) EPS. The firm’s quarterly revenue was down 3.4% on a year-over-year basis. Equities analysts expect that TherapeuticsMD Inc will post ($0.44) earnings per share for the current year.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.